A Phase 4 interventional study of Ramelteon 8mg and Placebo in Chronic Insomnia, sponsored by Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-11-20.
Sponsored by Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing ramelteon in Sleep Initiation and Maintenance Disorders — 1 open to participants now, 1 under way, 1 of them phase 3. ramelteon · Sleep Initiation and Maintenance Disorders.
Among the 36 studies testing ramelteon in Sleep Initiation and Maintenance Disorders, this one is the 29th largest by enrollment, is one of 2 that started in 2018, is one of 13 in phase 4, and was the 34th registered.
2,732 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 733 are open to participants now.
Browse Sleep Initiation and Maintenance Disorders studies →1 of the 36 studies testing ramelteon in Sleep Initiation and Maintenance Disorders is open now. Recruiting first, the newest first:
Nanjing Chia-tai Tianqing Pharmaceutical
Ages 18+
ramelteon: first FDA approval 2005 (ROZEREM). What it is approved for, and how studies give it, is on its page →
Of the 392 Sleep Initiation and Maintenance Disorders studies recruiting now, 155 (40%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 110 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 68 across 2,359 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Median enrollment 65 across the 36 interventional studies. Of the 30 that completed or were terminated, 13 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 36 have an industry lead sponsor. The 10 most frequent:
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan is the lead sponsor of 55 studies on the registry; 2 are open to participants now.
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan has 1 study filed under Sleep Initiation and Maintenance Disorders — fewer than ten, so there is no comparison to draw.
1 of the studies testing ramelteon in Sleep Initiation and Maintenance Disorders that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06512363Phase 3Nanjing Chia-tai Tianqing PharmaceuticalA Study of Ramelteon in Chinese Patients With Chronic Insomnia | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing ramelteon in Sleep Initiation and Maintenance Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To investigate effects on combination use of Ramelteon in the dose reduction or interruption process of (non-)BZD hypnotics during the dose reduction or interruption algorithm.
The hypnotic 'Ramelteon' does not have effect on Gamma Aminobutyric Acid (GABA-A) receptor that relates to the formation of addiction to the BZD or non-BZD hypnotics. Some results of clinical trials has been reported that the dose reduction or interruption of (non-)BZD hypnotics was achieved on combination use of Ramelteon by using its characteristic of the action mechanism with safely and effectively. However, these results have not been confirmed with randomized controlled trials.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects meeting Criteria 1 or 2 and Criteria 3 and all subsequent criteria will be included in the study:
Patients taking (non-)BZD hypnotics (including etizolam at bedtime) at a fixed dose in the following patterns since at least 1 month prior to consent (over 90% of drug compliance should be confirmed at the time of medical interview):
Patients taking 2 drugs at 2-fold of the usual dose (2 units) Patients whose total dosage are 2~4 units of 1~4 drugs can be also included. But attention needed not to conflict with exclusion criteria 2.
※Dosage cannot exceeded 2 units per 1 drug.
Exclusion Criteria:
Subjects meeting any of the following criteria will not be included in the study:
Patients taking anxiolytic or clonazepam at bedtime
*Patient taking anxiolytic and/or clonazepam at times except for bed-time will be included in the study. However, dosage and timing of administration can not be changed during the study period.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Co-administer following medication for 12 weeks since informed consent; R group: taking capsule of Ramelteon 8mg once daily before sleeping.
Drug: Ramelteon 8mg
Co-administer following medication for 12 weeks since informed consent; Placebo group: taking capsule of Placebo once daily before bedtime.
Drug: Placebo
Ramelteon 8mg once daily before bedtime for 12 weeks since informed consent
Placebo capsule once daily before bedtime for 12 weeks since informed consent
The achievement ratio of the 50% dose reduction of (non-)BZD hypnotics (Diazepam conversion value) at 12weeks or withdrawal without any deterioration of insomnia symptoms.
Evaluate the achievement ratio of the 50% or more of dose reduction by Participant's diary
Time frame: 12 weeks
The rate of subjects who achieved more than 50% dose reduction of (non-)BZD hypnotics (Diazepam conversion value) at 12 weeks or withdrawal since informed consent.
The rate of subjects who achieved more than 50% of dose reduction (Diazepam conversion value) will be assessed by Participant's diary
Time frame: 12 weeks
The achievement ratio of the 50% dose reduction (Diazepam conversion value) at 4weeks and 8weeks
The rate of subjects who achieved more than 50% dose reduction (Diazepam conversion value) will be assessed by Participant's diary
Time frame: at 4 weeks and 8weeks
The average of the dose reduction rate at 4weeks, 8weeks and 12weeks
The average of the dose reduction rate will be assessed by Participant's diary
Time frame: at 4 weeks, 8weeks and 12 weeks
The achievement ratio of the 100% dose reduction at 12weeks or withdrawal
The achievement ratio of the 100% dose reduction will be assessed by Participant's diary
Time frame: 12 weeks
The variation in total score of Pittsburg Sleep Quality Index (PSQI) at 4weeks, 8weeks and 12weeks
The variation in total score of PSQI will be assessed by the PSQI value sets sets at week 0, 4, 8 and 12. (The range of total score is 0-21. Higher scores represent worse tendency of the symptoms.)
Time frame: at 0, 4, 8 and 12 weeks
The variation in total score of Athens Insomnia Scale (AIS) at 4weeks, 8weeks and 12weeks
The variation in total score of AIS will be assessed by the AIS value sets at week 0, 4, 8 and 12. (The range of total score is 0-24. Higher scores represent worse tendency of the symptoms.)
Time frame: at 0, 4, 8 and 12 weeks
The variation in Patient health questionnaire (PHQ-9) score at 4weeks, 8weeks and 12weeks
The variation in PHQ-9 score will be assessed by the PHQ-9 value sets at week 0, 4, 8 and 12. (The range of total score is 0-27. Higher scores represent worse tendency of the symptoms.)
Time frame: at 0, 4, 8 and 12 weeks
Guide to the use of the clinical withdrawal assessment scale for benzodiazepines (CIWA-B) score at 4weeks, 8weeks and 12weeks
The variation in CIWA-B (Guide to the use of the clinical withdrawal assessment scale for benzodiazepines) score will be assessed by the CIWA-B value sets at week 4, 8 and 12. (The range of total score is 0-80. Higher scores represent worse tendency of the symptoms.)
Time frame: at 4, 8 and 12 weeks
Patient global impression of therapy (PGI) score at 12weeks or withdrawal
PGI(Patient global impression of therapy) score will be assessed by the PGI value sets at 12weeks or withdrawal. (The range of total score is 0-21. Higher scores represent worse tendency of the symptoms.)
Time frame: 12 weeks
The variation in Ben-dep(Benzodiazepine Dependence Self-Report Questionnaire) score at 12weeks or withdrawal
The variation in Ben-dep score will be assessed by the Ben-dep value sets at 0 and 12weeks or withdrawal. (The range of total score is 0-100. Higher scores represent worse tendency of the symptoms.)
Time frame: at 0 and 12 weeks
Adverse Events
Adverse Events will be determined by the latest version of MedDRA/J (Medical Dictionary for Regulatory Activities/J).
Time frame: 12 weeks
Ran from Feb 2018 to primary completion in Jul 2019, 17 months.
Of 52 non-industry phase 4 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 59. This study's 17 months is below that.
Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ramelteon
Sleep Initiation and Maintenance Disorders →
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan